Merck's CETP Inhibitor Anacetrapib Will Enter Phase III In 2008, With Cardiovascular Outcomes Study To Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will go ahead with Phase III program after reviewing Phase III data on Pfizer's failed CETP inhibitor torcetrapib.